| Pharmaceutical Information |
| Drug Name |
Velaglucerase alfa |
| Drug ID |
BADD_D02343 |
| Description |
Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease. |
| Indications and Usage |
Velaglucerase alfa is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease. |
| Marketing Status |
Not Available |
| ATC Code |
A16AB10 |
| DrugBank ID |
DB06720
|
| KEGG ID |
D09029
|
| MeSH ID |
Not Available
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0G5ET
|
| NDC Product Code |
54092-701 |
| Synonyms |
Not Available |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
884604-91-5 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
